1.Halperin, SA et al. (2012) The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(suppl. 2), B26–B36.
2.O'Lorcain, P and Bennett, DE et al. (2018) A retrospective assessment of the completeness and timeliness of meningococcal disease notifications in the Republic of Ireland over a 16-year period, 1999–2015. Public Health 156, 44–51.
3.Bennett, DE and Cafferkey, MT (2006) Consecutive use of two multiplex PCR-based assays for simultaneous identification and determination of capsular status of nine common Neisseria meningitidis serogroups associated with invasive disease. Journal of Clinical Microbiology 44, 1127–1131.
4.Whittaker, R et al. (2017) The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine 35, 2034–2041.
6.Maiden, MCJ et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. The Journal of Infectious Diseases 197, 737–743.
7.Trotter, CL and Maiden, MCJ (2009) Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Review of Vaccines 8, 851–861.
8.Kabir, Z et al. (2010) Active smoking and second-hand-smoke exposure at home among Irish children, 1995–2007. Archives of Disease in Childhood 95, 42–45.
9.Stoof, SP et al. (2015) Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clinical Infectious Diseases 61, 1281–1292.
10.Hellenbrand, W et al. (2013) Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine. The Journal of Infection, 66, 48–56.
11.Bijlsma, MW et al. (2014) Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data. The Lancet Infectious Diseases, 14, 805–812.
12.Hedberg, ST et al. (2011) Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro surveillance 16, 1–7.
13.Bröker, M et al. (2014) Meningococcal serogroup Y emergence in Europe: high importance in some European regions in 2012. Human Vaccines & Immunotherapeutics 10, 1725–1728.
14.Bröker, M et al. (2015) Meningococcal serogroup y disease in Europe: continuation of high importance in some European regions in 2013. Human Vaccines and Immunotherapeutics 11, 2281–2286.
15.Ladhani, SN et al. (2015) Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and wales. Clinical Infectious Diseases 60, 578–585.
16.Ladhani, SN et al. (2012) Invasive meningococcal capsular group Y disease, England and Wales, 2007–2009. Emerging Infectious Diseases 18, 64–70.
17.European Centre for Disease Prevention and Control (2016) Annual Epidemiological Report 2016 – Invasive meningococcal disease. [Internet]. Stockholm: ECDC; [cited 2017 June 10]. Available at .
18.Edge, C et al. (2016) Clinical diagnoses and outcomes of 4619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: linkage analysis of multiple national databases. The Journal of Infection Elsevier Ltd, 73, 427–436.
19.Muscat, M et al. (2009) Invasive meningococcal disease in Malta: an epidemiological overview, 1994–2007. Journal of Medical Microbiology 58, 1492–1498.
20.Guerra-Silveira, F and Abad-Franch, F (2013) Sex bias in infectious disease epidemiology: patterns and processes. PLoS ONE 8, e62390.
21.Dias, SP et al. (2017) Sex-based differences in adults with community-acquired bacterial meningitis: a prospective cohort study. Clinical Microbiology and Infection 23, 121.e9–121.e15.
22.Dharmarajan, L, Salazar, L and Hasbun, R (2016) Gender differences in community-acquired meningitis in adults: clinical presentations and prognostic factors. Journal of Meningitis 1, 255–269.
23.Muenchhoff, M and Goulder, PJR (2014) Sex differences in pediatric infectious diseases. Journal of Infectious Diseases 209(suppl. 3), S120-S126.
24.Gunaratnam, P et al. (2013) Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012. Western Pacific Surveillance and Response Journal: WPSAR 4, 4–10.
25.O'Ryan, M et al. (2014) A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs 74, 15–30.
26.Serruto, D et al. (2012) The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(suppl. 2), B87–B97.
27.Medini, D, Stella, M and Wassil, J (2015) MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine, 33, 2629–2636.
28.Ladhani, SN et al. (2016) Enter B and W: two new meningococcal vaccine programmes launched. Archives of disease in childhood 101, 91–95.
29.Clarke, SC et al. (2002) Laboratory confirmation of meningococcal disease in Scotland, 1993–9. Journal of clinical pathology 55, 32–36.
30.Heinsbroek, E et al. (2013) Added value of PCR-testing for confirmation of invasive meningococcal disease in England. The Journal of Infection, 67, 385–390.
31.Tzanakaki, G et al. (2003) Evaluation of non-culture diagnosis of invasive meningococcal disease by polymerase chain reaction (PCR). FEMS Immunology & Medical Microbiology 39, 31–36.
32.Anson, LW et al. (2018) DNA extraction from primary liquid blood cultures for bloodstream infection diagnosis using whole genome sequencing. Journal of Medical Microbiology 67, 347–357.
33.Rossen, JWA, Friedrich, AW and Moran-Gilad, J (2018) Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology. Clinical Microbiology and Infection, 24, 355–360.
34.Klughammer, J et al. (2017) Comparative genome sequencing reveals within-host genetic changes in Neisseria meningitidis during invasive disease. PLoS ONE 12, 1–29.
35.Lucidarme, J et al. (2017) Frequent capsule switching in ‘ultra-virulent’ meningococci – are we ready for a serogroup B ST-11 complex outbreak? Journal of Infection 75, 95–103.
36.Brehony, C (2016) Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine 34, 4690–4697.